Sodium Chloride 0.45 % w/v and Glucose 2.5% w/v Solution for Infusion BP Ireland - English - HPRA (Health Products Regulatory Authority)

sodium chloride 0.45 % w/v and glucose 2.5% w/v solution for infusion bp

baxter healthcare limited - sodium chloride; sodium chloride; glucose monohydrate; glucose monohydrate - solution for infusion - 0.45 2.5 percent weight/volume - salt solutions; sodium chloride

Sodium Chloride 0.9 % w/v and Glucose 5% w/v Solution for Infusion BP (Viaflo container) Ireland - English - HPRA (Health Products Regulatory Authority)

sodium chloride 0.9 % w/v and glucose 5% w/v solution for infusion bp (viaflo container)

baxter healthcare limited - sodium chloride; sodium chloride; glucose monohydrate; glucose monohydrate - solution for infusion - 0.9/5 %w/v percent weight/volume - salt solutions; sodium chloride

Sodium Iodide (I131) Capsule T 37-7400 MBq hard capsule Ireland - English - HPRA (Health Products Regulatory Authority)

sodium iodide (i131) capsule t 37-7400 mbq hard capsule

curium netherlands b.v. - sodium iodide (131 i) - capsule, hard - 37-7400 megabecquerel(s) - iodine (131i) compounds; sodium iodide (131i)

Potassium Chloride 0.15% w/v & Glucose 5% w/v Solution for Infusion Ireland - English - HPRA (Health Products Regulatory Authority)

potassium chloride 0.15% w/v & glucose 5% w/v solution for infusion

fresenius kabi limited - potassium chloride; glucose monohydrate - solution for infusion - 0.15 + 5 percent weight/volume - solutions affecting the electrolyte balance; electrolytes with carbohydrates - blood substitutes and perfusion solutions; electrolytes with carbohydrates - prevention and treatment of potassium depletion and/or hypokalaemia in cases where supply of water and carbohydrates is required due to either restriction of the intake of fluids and electrolytes or depletion by normal routes

Potassium Chloride 0.3% w/v & Glucose 5% w/v Solution for Infusion Ireland - English - HPRA (Health Products Regulatory Authority)

potassium chloride 0.3% w/v & glucose 5% w/v solution for infusion

fresenius kabi limited - potassium chloride; glucose monohydrate - solution for infusion - 0.3 + 5 percent weight/volume - solutions affecting the electrolyte balance; electrolytes with carbohydrates - blood substitutes and perfusion solutions; electrolytes with carbohydrates - prevention and treatment of potassium depletion and/or hypokalaemia in cases where supply of water and carbohydrates is required due to either restriction of the intake of fluids and electrolytes or depletion by normal routes.

AMCLAVOX DUO 500/125, amoxicillin (as trihydrate) 500 mg and clavulanic acid (as potassium) 125 mg tablets blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

amclavox duo 500/125, amoxicillin (as trihydrate) 500 mg and clavulanic acid (as potassium) 125 mg tablets blister pack

arrotex pharmaceuticals pty ltd - potassium clavulanate, quantity: 151.917 mg; amoxicillin trihydrate, quantity: 573.892 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; dichloromethane; isopropyl alcohol; sodium starch glycollate; titanium dioxide; hypromellose; propylene glycol; purified talc; ethylcellulose - amclavox duo 500/125 tablets are indicated for short-term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (complicated and uncomplicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets preparations should not require the addition of another antibiotic due to the amoxicillin content of these products.

PREPOPIK- sodium picosulfate, magnesium oxide, and anhydrous citric acid powder, metered United States - English - NLM (National Library of Medicine)

prepopik- sodium picosulfate, magnesium oxide, and anhydrous citric acid powder, metered

ferring pharmaceuticals inc. - sodium picosulfate (unii: lr57574hn8) (deacetylbisacodyl - unii:r09078e41y), magnesium oxide (unii: 3a3u0gi71g) (magnesium cation - unii:t6v3lhy838), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - sodium picosulfate 10 mg in 16.1 g - prepopik® is indicated for cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients 9 years of age and older. prepopik is contraindicated in the following conditions: - patients with severe renal impairment (creatinine clearance less than 30 ml/minute) which may result in accumulation of magnesium [see warnings and precautions (5.4)] - gastrointestinal obstruction or ileus [see warnings and precautions (5.6)] - bowel perforation [see warnings and precautions (5.6)] - toxic colitis or toxic megacolon - gastric retention - hypersensitivity to any of the ingredients in prepopik [see adverse reactions (6.2)] risk summary there are no data with prepopik use in pregnant women to determine a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in an animal reproduction study, no adverse developmental effects were observed in pregnant rats when sodium picosulfate, magnesium oxide, and anhydrous citric acid were administered orally at doses 1

BAXTER POTASSIUM CHLORIDE 40 mmol and 0.9% SODIUM CHLORIDE 100 mL intravenous infusion bag Australia - English - Department of Health (Therapeutic Goods Administration)

baxter potassium chloride 40 mmol and 0.9% sodium chloride 100 ml intravenous infusion bag

baxter healthcare pty ltd - potassium chloride, quantity: 29.8 g/l; sodium chloride, quantity: 9 g/l - injection, intravenous infusion - excipient ingredients: water for injections - the baxter potassium chloride and sodium chloride intravenous infusion is indicated as a source of water and to restore electrolyte balance as required by the patient's clinical condition, such as hypokalaemia.

SODIUM CHLORIDE irrigant United States - English - NLM (National Library of Medicine)

sodium chloride irrigant

cardinal health - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37) - sodium chloride 0.9 g in 100 ml

Potassium chloride 0.3% (potassium 40mmol/1litre) / Glucose 4% / Sodium chloride 0.18% infusion 1litre Viaflex bags United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium chloride 0.3% (potassium 40mmol/1litre) / glucose 4% / sodium chloride 0.18% infusion 1litre viaflex bags

potassium 40mmol/1litre) / glucose 4% / sodium chloride 0.18% infusion 1litre viaflex bags (baxter healthcare ltd - glucose anhydrous; potassium chloride; sodium chloride - infusion - 40mg/1ml ; 3mg/1ml ; 1.8mg/1ml